NCT04633902 - Phase II Study of Olaparib and Pembrolizumab in Advanced Melanoma With Homologous Recombination (HR) Mutation | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 3, 2021

Primary Completion Date

June 30, 2023

Study Completion Date

December 31, 2024

Conditions

Metastatic Melanoma

Interventions

DRUG

Olaparib

Olaparib 300 mg BID daily

DRUG

Pembrolizumab

Pembrolizumab 200 mg IV eveyr 3 weeks (for up to 2 years)

Trial Locations (2)

RECRUITING

The University of Texas MD Anderson Cancer Center, Houston

RECRUITING

California Pacific Medical Center Research Institute, San Francisco